Quintessence Biosciences, Inc.

Quintessence Biosciences is a biopharmaceutical company that specializes in creating innovative protein-based therapeutics to combat cancer. Their product line includes Evade RNase QBI-139, which has been successful in inhibiting tumor growth in various types of cancer such as breast, colorectal, non-small cell lung, ovarian, pancreatic, and prostate cancer. Additionally, they offer targeted EVade ribonucleases, a tumor-targeting therapy, and EVade ribonuclease zymogens, which are inactive enzyme precursors that become active through proteolytic cleavage. All of these products are based on the company's proprietary Evade ribonuclease technology, which enables the engineering of human proteins (ribonucleases) for the treatment of human diseases.